Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : The collaboration aims to accelerate patient identification and recruitment for Prothena’s ASCENT-2 clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatmen...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
April 13, 2023
Lead Product(s) : Fish Oil
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : University of Mississippi, Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Method of Fish Oil Administration on Patient Compliance
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 16, 2011
Lead Product(s) : Fish Oil
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : University of Mississippi, Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable